Hidradenitis Suppurativa – Drugs in Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hidradenitis Suppurativa – Drugs in Development, 2021, provides an overview of the Hidradenitis Suppurativa (Dermatology) pipeline landscape.

Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks and under the breasts.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hidradenitis Suppurativa – Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hidradenitis Suppurativa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 14, 7, 1, 9 and 3 respectively.

Hidradenitis Suppurativa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa (Dermatology).

– The pipeline guide reviews pipeline therapeutics for Hidradenitis Suppurativa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Hidradenitis Suppurativa (Dermatology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Hidradenitis Suppurativa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hidradenitis Suppurativa (Dermatology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hidradenitis Suppurativa (Dermatology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AbbVie Inc

Aclaris Therapeutics Inc

Afecta Pharmaceuticals Inc

Alvotech ehf

Amgen Inc

AnaptysBio Inc

AstraZeneca Plc

Attillaps Holdings Inc

BioXpress Therapeutics SA

ChemoCentryx Inc

CSL Ltd

Table of Contents

Table of Contents

Introduction

Hidradenitis Suppurativa - Overview

Hidradenitis Suppurativa - Therapeutics Development

Hidradenitis Suppurativa - Therapeutics Assessment

Hidradenitis Suppurativa - Companies Involved in Therapeutics Development

Hidradenitis Suppurativa - Drug Profiles

Hidradenitis Suppurativa - Dormant Projects

Hidradenitis Suppurativa - Discontinued Products

Hidradenitis Suppurativa - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Hidradenitis Suppurativa, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Hidradenitis Suppurativa – Pipeline by AbbVie Inc, 2021

Hidradenitis Suppurativa – Pipeline by Aclaris Therapeutics Inc, 2021

Hidradenitis Suppurativa – Pipeline by Afecta Pharmaceuticals Inc, 2021

Hidradenitis Suppurativa – Pipeline by Alvotech ehf, 2021

Hidradenitis Suppurativa – Pipeline by Amgen Inc, 2021

Hidradenitis Suppurativa – Pipeline by AnaptysBio Inc, 2021

Hidradenitis Suppurativa – Pipeline by AstraZeneca Plc, 2021

Hidradenitis Suppurativa – Pipeline by Attillaps Holdings Inc, 2021

Hidradenitis Suppurativa – Pipeline by BioXpress Therapeutics SA, 2021

Hidradenitis Suppurativa – Pipeline by ChemoCentryx Inc, 2021

Hidradenitis Suppurativa – Pipeline by CSL Ltd, 2021

Hidradenitis Suppurativa – Pipeline by Eli Lilly and Co, 2021

Hidradenitis Suppurativa – Pipeline by Ichnos Sciences Inc, 2021

Hidradenitis Suppurativa – Pipeline by Immunwork Inc, 2021

Hidradenitis Suppurativa – Pipeline by Incyte Corp, 2021

Hidradenitis Suppurativa – Pipeline by InflaRx NV, 2021

Hidradenitis Suppurativa – Pipeline by Innovation Pharmaceuticals Inc, 2021

Hidradenitis Suppurativa – Pipeline by InSight Biopharmaceuticals Ltd, 2021

Hidradenitis Suppurativa – Pipeline by Johnson & Johnson, 2021

Hidradenitis Suppurativa – Pipeline by Kiniksa Pharmaceuticals Ltd, 2021

Hidradenitis Suppurativa – Pipeline by Kymera Therapeutics LLC, 2021

Hidradenitis Suppurativa – Pipeline by Lytix Biopharma AS, 2021

Hidradenitis Suppurativa – Pipeline by NeuClone Pty Ltd, 2021

Hidradenitis Suppurativa – Pipeline by NovaRock Biotherapeutics Inc, 2021

Hidradenitis Suppurativa – Pipeline by Novartis AG, 2021

Hidradenitis Suppurativa – Pipeline by Pfizer Inc, 2021

Hidradenitis Suppurativa – Pipeline by Pharmapraxis, 2021

Hidradenitis Suppurativa – Pipeline by Staidson (Beijing) Biopharmaceuticals Co Ltd, 2021

Hidradenitis Suppurativa – Pipeline by UCB SA, 2021

Hidradenitis Suppurativa – Pipeline by VYNE Therapeutics Inc, 2021

Hidradenitis Suppurativa – Dormant Projects, 2021

Hidradenitis Suppurativa – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Hidradenitis Suppurativa, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports